Cost–utility analysis of latanoprost unidose cationic emulsion preservative-free versus latanoprost unidose in the treatment of open-angle glaucoma and ocular hypertension patients in Spain
CE-latanoprost unidose was a cost-effective option for the treatment of patients with OAG/OHT and OSD in comparison to latanoprost unidose (non-emulsion formulation). In addition to its clinical benefits, the economic analysis supports using CE-latanoprost in terms of efficiency.
Authors
- Tamara del Río (ORCID: https://orcid.org/0009-0007-8961-5667)
- Nataly Espinoza-Cámac (ORCID: https://orcid.org/0000-0002-8116-6963)
- Fernando López-López (ORCID: https://orcid.org/0000-0003-0460-068X)
- Itziar Oyagüez (ORCID: https://orcid.org/0000-0002-3047-6152)
- María Isabel Canut
- Marta Pazos (ORCID: https://orcid.org/0000-0003-4094-6346)
- José Manuel Larrosa Poves (ORCID: https://orcid.org/0000-0002-6745-7668)
- María C Rodríguez-Vázquez (ORCID: https://orcid.org/0009-0004-0098-211X)
Institutions
- Universidad Complutense de Madrid (ES)
- Santen (Japan) (JP)
- Hospital Clínico San Carlos (ES)
- Hospital Universitario Miguel Servet (ES)
- Hospital Clínic de Barcelona (ES)
- Santen (United Kingdom) (GB)
- Hospital Clínico de la Universidad de Chile (CL)
- Hospital Central de la Defensa Gómez Ulla (ES)
- Pharmacoeconomics and Health Outcomes Research Iberia (Spain) (ES)
Publication Details
- Journal
- Expert Review of Pharmacoeconomics & Outcomes Research
- Published
- 2025-09-04
- DOI
- https://doi.org/10.1080/14737167.2025.2556693
- Citations
- 1
- Primary Topic
- Glaucoma and retinal disorders
- Type
- article
- Field-Weighted Citation Impact
- 1.71